A qualitative study of 72 Canadians aged 60 and older finds that older adults use cannabis primarily for pain, sleep, and anxiety, but consistently report that health care providers are an absent or inadequate source of guidance. Despite legalization, stigma persists and the clinical infrastructure has not kept pace with rising use in this population.

Older adults are the fastest-growing segment of cannabis consumers in Canada, and many are managing chronic pain, anxiety, and sleep disturbances with products whose potency, dosing, and drug interaction profiles they do not fully understand. When these patients turn to their health care providers, they frequently encounter silence, discomfort, or outright dismissal. This study puts direct testimony behind what many clinicians quietly suspect: the clinical infrastructure around cannabis and older adults is failing at the point of greatest need.

Cannabis use among adults over 60 has risen substantially since Canadian legalization in 2018, yet this population remains poorly characterized in the research literature. Older adults face a unique intersection of chronic disease burden, polypharmacy, altered drug metabolism, and increased vulnerability to adverse effects including falls and cognitive decline. This study sought to understand how 72 older Canadians across five regions experience and perceive cannabis, using a phenomenological qualitative design with online focus groups segmented by frequency of use. The mechanistic rationale for the study is not pharmacological but epidemiological: a rapidly growing consumer segment is making health decisions with limited clinical infrastructure to support them.

Five overarching themes emerged. Participants reported using cannabis primarily for pain, sleep, and anxiety, with edibles and topicals preferred by female participants and smoking and vaping more common among males. Both frequent and infrequent users expressed genuine concern about cognitive decline, lung damage, and drug interactions, particularly with blood thinners and sedatives. Participants described difficulty understanding dosing and onset times for edibles, aligning with documented overconsumption risks in this age group. The most consistent finding across all subgroups was that health care providers are perceived as an inadequate or absent source of cannabis guidance. The authors conclude that targeted public education materials, clinician training, and further quantitative and clinical research are urgently needed to address this documented gap.

The Guidance Gap: Cannabis Use in Adults Over 60 and What the Health System Is Missing

Somewhere in Canada right now, an older adult is quietly adjusting their arthritis medication routine, adding a CBD gummy they read about online, and hoping their doctor doesn’t ask, because they’re not sure their doctor would know what to say anyway. This study by Renard and colleagues doesn’t pretend to answer whether cannabis works for the pain, sleep, or anxiety these older patients are pursuing. What it does, and does well, is document the texture of a clinical vacuum. Seventy-two adults over 60, segmented by use frequency and distributed across five Canadian regions, sat in virtual focus groups and told researchers something remarkably consistent: they are making complex pharmacological decisions, often involving products with variable potency and unpredictable onset, without meaningful input from anyone in the health care system. The paper’s greatest contribution is not the catalogue of reasons why older adults use cannabis or the gender-based patterns in consumption method. It is the clarity with which it identifies where the system breaks down. This is not a study that proves cannabis helps arthritis. It is a study that proves we are not having the conversation.

I should be honest about what the study cannot tell us, and where caution is warranted. The recruitment method, relying on a commercial panel database and social media outreach, almost certainly captured the most digitally literate, health-engaged, and cannabis-accepting older adults in Canada. Imagine trying to understand what all older drivers think about road safety by recruiting only people who responded to a driving club newsletter. You would hear from engaged, experienced drivers, but you would systematically miss those who had already had accidents or stopped driving entirely. The older adults most at risk from cannabis, those who are cognitively impaired, socially isolated, or managing cannabis use alongside heavy polypharmacy, are very likely not represented in these focus groups. Similarly, when participants report that cannabis helps their pain or sleep, that is self-reported therapeutic benefit without any controlled condition. It is like asking someone who takes a warm bath whether it helps their arthritis, and then concluding that warm baths treat arthritis. It may well be true. But this method simply cannot tell us that. The gender differences described are qualitative impressions from very small subgroups, not statistically tested categories. They should be treated as hypothesis-generating observations, nothing more.

What I would tell a patient who brought this study to an appointment is straightforward: it matters that you are telling me you use cannabis, and I want to understand what you are using, how much, and in what form, because interactions with your other medications are real, potency today is very different from what you may recall from decades past, and I want to help you make this as safe as possible. What I would tell a colleague is that this paper confirms what many of us already sense in practice: our older patients are using cannabis and not disclosing it, largely because we have not created the clinical space for the conversation. We need to ask, and we need to know enough to offer something better than reflexive discouragement. What I would tell a policymaker is that this study identifies a systemic gap, not an individual failure, and that investment in clinician education and age-appropriate public health materials is a documented, cross-regional need. When a new or expanding exposure reaches a vulnerable population and clinical infrastructure fails to keep pace, patients fill the guidance vacuum themselves, sometimes wisely, sometimes not. The appropriate response is not to dismiss patient-driven therapeutic use but to professionalize the conversation around it.

This study sits at the exploratory stage of the research arc. It generates hypotheses rather than testing them. The five themes it identifies, ranging from consumption practices and knowledge gaps to perceived harms and evolving stigma, map the terrain that future quantitative surveys, cohort studies, and clinical trials will need to traverse. The segmentation by use frequency and region provides some analytical scaffolding, but each subgroup cell of six to eight participants limits the depth of any within-group conclusions. This is the kind of evidence that tells us where to look, not what we will find when we get there.

From a pharmacological perspective, the concerns raised by participants are well-founded. Cannabis, particularly THC-dominant products, carries documented interaction potential with anticoagulants such as warfarin, sedative and hypnotic medications, and certain antidepressants through cytochrome P450 enzyme inhibition. In a population already managing multiple medications with narrow therapeutic windows, unmonitored cannabis use introduces real risk. The reported difficulty understanding edible onset times and appropriate dosing aligns with emergency department data on older adult overconsumption events. Clinicians should begin routinely and non-judgmentally asking older patients about cannabis use during medication reconciliation, and should develop at least baseline familiarity with the pharmacokinetic profiles of common cannabis product categories.

This is an original peer-reviewed qualitative study using a phenomenological design and thematic analysis of online focus group data. In the evidence hierarchy, qualitative research occupies a distinct role: it generates descriptive understanding of lived experience and formulates hypotheses, but it is not designed to test those hypotheses, estimate prevalence, or establish causal relationships. The single most important inference constraint is that no finding from this study can be treated as representative of all older Canadian cannabis users or as evidence of clinical efficacy for any condition.

This study is broadly consistent with the growing body of survey and qualitative evidence showing that older adult cannabis use is increasing post-legalization and that therapeutic motivations dominate. Data from the International Cannabis Policy Study (2018 to 2021) documented rising past-12-month use among adults aged 55 to 65 in Canada, providing a quantitative backdrop to the qualitative themes identified here. The concerns about harms, particularly cognitive decline and drug interactions, align with findings from a scoping review of cannabis use in older adults that concluded harms may outweigh benefits, though much of the included evidence was of low quality. Where this study extends the literature is in its structured, multi-region exploration of the clinical guidance gap, which has been noted in prior work but rarely documented with this degree of participant specificity. The gender-based patterns in method preference, while preliminary, add a dimension that most existing quantitative surveys have not explored in this age group.

The most consequential analytic choice was the decision to segment focus groups primarily by frequency of use rather than by health status, medication burden, or specific therapeutic goal. A segmentation that separated, for example, participants managing chronic pain from those using cannabis recreationally might have produced sharper thematic distinctions around clinical decision-making and perceived efficacy. Additionally, the thematic analysis used an inductive/deductive hybrid approach, which inherently reflects researcher framing to some degree. A purely grounded theory approach, or the addition of member checking where participants validated identified themes, might have surfaced themes the current approach missed, particularly around financial barriers to legal cannabis or the role of informal markets, neither of which received meaningful attention in the reported findings.

The most likely overinterpretation is treating participant-reported therapeutic benefits, such as pain relief, better sleep, or reduced anxiety, as evidence that cannabis is clinically effective for these conditions in older adults. This study documents what participants believe and experience; it cannot confirm whether those experiences reflect genuine pharmacological effects, placebo responses, or reporting bias shaped by focus group dynamics. Relatedly, the observed gender differences in consumption method should not be interpreted as established population-level patterns. They are qualitative impressions from very small, self-selected subgroups. Finally, the finding that legalization has partially reduced stigma should not be generalized beyond these 72 individuals who were, by definition, willing to discuss their cannabis use with strangers on a video call.

This study contributes a richly structured qualitative portrait of how older Canadians experience and perceive cannabis post-legalization, organized by use frequency and region. It does not establish that cannabis is effective for any specific condition in this population, nor can its findings be generalized quantitatively. What it documents clearly and consistently is a clinical guidance gap that has immediate implications for primary care practice, clinician education, and public health communication aimed at older adults.

Does this study prove that cannabis works for pain or sleep in older adults?

No. This study documents what participants reported experiencing, not whether cannabis actually produced those effects. Qualitative focus group data cannot establish clinical efficacy. Controlled trials would be needed to determine whether cannabis reliably treats pain, sleep disturbances, or anxiety in adults over 60.

Should older adults tell their doctor they are using cannabis?

Absolutely. Cannabis interacts with several common medications, including blood thinners, sedatives, and certain antidepressants. Many of these interactions have real clinical consequences, particularly in older adults who metabolize drugs differently. Disclosure allows your physician to monitor for interactions, adjust doses, and help you use cannabis more safely.

Why don’t doctors know more about cannabis?

Most physicians received little or no formal training on cannabinoid pharmacology during medical school or residency. Legalization has outpaced clinical education, and many providers feel uncomfortable discussing cannabis because they lack the knowledge base to do so confidently. This study highlights that gap from the patient side, and it is increasingly recognized as a systemic problem requiring targeted professional development.

Are edibles safer than smoking for older adults?

Edibles avoid the respiratory risks associated with smoking, which is why some participants in this study reported switching to oral forms as they aged. However, edibles carry their own risks: delayed onset (often 60 to 120 minutes) can lead to accidental overconsumption, and the effects are generally longer-lasting and harder to titrate. Neither route is without risk, and both require informed, individualized guidance.

Have thoughts on this? Share it: